Butyzamide

SKU: orb1741367

Description

Butyzamide is a novel, orally active small molecule thrombopoietin receptor (Mpl) agonist. It stimulates cellular proliferation and activates JAK/STAT and MAPK signaling pathways in vitro, and has demonstrated efficacy in elevating platelet counts in mouse xenotransplantation models.

Research Area

Cardiovascular Research, Epigenetics & Chromatin, Immunology & Inflammation, Signal Transduction, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 1110767-45-7
• MW: 591.55
• Purity: >99.99% (May vary between batches)
• Formula: C₂₉H₃₂Cl₂N₂O₅S
• SMILES: O(C)C1=C(C=CC=C1C(OCCC)C(C)(C)C)C=2N=C(NC(=O)C3=CC(Cl)=C(/C=C(/C(O)=O)\C)C(Cl)=C3)SC2
• Target: p38 MAPK,Thrombopoietin Receptor,JAK,STAT
• Solubility: DMSO:165 mg/mL (278.93 mM)

Bioactivity

• In Vivo:
  Butyzamide (10 mg/kg, 50 mg/kg; oral administration; once daily for 20 days) enhances human platelet levels in NOG mice transplanted with human fetal liver-derived CD34+ cells.
• In Vitro:
  Butyzamide (3 μM; 15 minutes) induces phosphorylation of JAK2, STAT3, STAT5, and MAPK in Ba/F3-hMpl cells. Butyzamide (3 μM; 48 hours) induces colony-forming unit-megakaryocyte (CFU-MK) and polyploid megakaryocyte formation in human CD34+ hematopoietic progenitor cells.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Butyzamide, JAK, TPO, ThrombopoietinReceptor, Thrombopoietin Receptor

Compound Identifiers

PubChem CID

44602781